Joseph J. Larosa - 08 Dec 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP General Counsel and Secret
Signature
/s/**Joseph LaRosa
Issuer symbol
REGN
Transactions as of
08 Dec 2023
Net transactions value
-$1,283,605
Form type
4
Filing time
12 Dec 2023, 16:01:54 UTC
Previous filing
27 Mar 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability $718,909 -852 -2.9% $843.79 28,572 08 Dec 2023 Direct
transaction REGN Common Stock Award $0 +2,133 +7.5% $0.000000 30,705 08 Dec 2023 Direct F1
transaction REGN Common Stock Tax liability $564,696 -669 -2.2% $844.09 30,036 11 Dec 2023 Direct
holding REGN Common Stock 3,367 08 Dec 2023 2022 GRAT
holding REGN Common Stock 355 08 Dec 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +7,649 $0.000000 7,649 08 Dec 2023 Common Stock 7,649 $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.